Reply to the Letter to the Editor 'Risk of MDS/AML with the addition of neoadjuvant carboplatin to standard chemotherapy for triple-negative breast cancer' by A. Okines and N. Turner.

Geyer, C E; Sikov, W M; Loibl, S

Geyer, C E; Sikov, W M; Loibl, S.

Affiliation

Geyer CE; UPMC Hillman Cancer Center, Pittsburgh, USA. Electronic address: charles.geyer@nsatp.org.
Sikov WM; Breast Health Center, Women & Infants Hospital of Rhode Island, Providence, USA.
Loibl S; Department of Medicine and Research, German Breast Group, Neu-Isenburg, Germany.

Ann Oncol ; 33(7): 739-740, 2022 07.

Article in En | MEDLINE | ID: mdl-35390464

Subject(s)

Leukemia, Myeloid, Acute; Triple Negative Breast Neoplasms; Antineoplastic Combined Chemotherapy Protocols/adverse effects; Carboplatin/therapeutic use; Humans; Leukemia, Myeloid, Acute/drug therapy; Neoadjuvant Therapy/adverse effects; Paclitaxel/therapeutic use; Triple Negative Breast Neoplasms/drug therapy

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Leukemia, Myeloid, Acute / Triple Negative Breast Neoplasms Type of study: Etiology_studies / Risk_factors_studies Limits: Humans Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2022 Document type: Article

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google